Get the latest Science News and Discoveries

In the PAPILLON study, first-line amivantamab-chemotherapy demonstrates the longest overall survival reported for EGFR exon 20 insertion-positive advanced NSCLC

None

Related news:

Perioperative atezolizumab plus chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC

Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC

Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC